Medical Disposables and Supplies Limited (MDS), a prominent distributor of pharmaceutical and medical supplies, has embarked on a strategic initiative to reverse its financial losses and return to profitability. Despite two consecutive years of net losses, the company has outlined a four-pronged approach to address its challenges and restore financial health. This strategy includes aggressive cost reduction, restoration of gross margins, debt reduction, and an expanded product offering in both its medical and consumer divisions.
MDS, which has been listed on the Jamaica Stock Exchange (JSE) for nearly 12 years, has seen significant growth in revenue, assets, and capital base since its listing. However, the company faced setbacks due to the write-down of COVID-19 backlogged products in its March 2024 financial year and rising operational financing costs in 2025. These challenges have necessitated a sharp focus on cost management and operational efficiency.
In its 2025 annual report, MDS highlighted progress in revenue growth, expanded product offerings, and stronger gross margins. Consolidated revenue grew by 5% to $3.88 billion, driven by increased sales volumes and market diversification. Gross profit rose by 22% to $876.43 million, though real growth was only 10.64% after accounting for inventory write-downs. Administrative expenses increased by 8% due to emergency repairs and higher security costs, while selling and promotional expenses were reduced by 4%.
However, MDS faced a significant jump in impairment charges on financial assets, from $14.97 million to $129.17 million, largely due to auditors increasing provisions for related party balances. This resulted in a consolidated operating loss of $151.66 million and a net loss of $281.06 million. Despite these setbacks, the company’s core business showed improvement, with revenue growing by 9% to $3.52 billion and gross profit rising by 38% to $787.29 million.
MDS CEO Kurt Boothe emphasized the company’s focus on cost containment, supplier renegotiations, and operational efficiency. The company has also expanded its presence in the general consumer market, with confectionery, beauty, and household lines contributing to revenue growth. MDS expects finance costs to decline in the coming months as it optimizes inventory levels and enhances collections performance.
The company’s first quarter (April to June) saw a 3% rise in consolidated revenue to $998.74 million but a net loss of $16.42 million. MDS’s asset base stood at $2.49 billion, with inventory at $1.04 billion and trade receivables at $626.19 million. The company last paid a dividend in January 2023 and is currently focused on financial recovery. MDS will host its annual general meeting on November 20 at its head office in Kingston.